FLT3 and acute myeloid leukemia: Treatment resistance in patients with FLT3 mutation-positive AML is also facilitated by the overexpression of the FLT3 ligand, anti-apoptotic proteins, and AXL, an oncogenic tyrosine kinase that facilitates FLT3 activation [9–12].